trending Market Intelligence /marketintelligence/en/news-insights/trending/ih318ypytq861sa9tbhx1a2 content esgSubNav
In This List

Summit Therapeutics to raise £15M in share offering

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Summit Therapeutics to raise £15M in share offering

Summit Therapeutics plc is looking to raise up to about £15.0 million via the sale of 8,333,333 shares at £1.80 each.

The U.K. biotechnology company will use the funds to develop its Duchenne muscular dystrophy drug ezutromid and to further its utrophin modulator and infectious disease pipeline.

Panmure Gordon (U.K.) Ltd. and Nplus1 Singer Advisory LLP are acting as joint brokers and joint book runners in the placing, with Cairn Financial LLP as a nominated adviser.